Can a common blood pressure drug protect the placenta in Early-Onset preeclampsia?

NCT ID NCT07738562

Not yet recruiting Disease control Sponsor: Hadassah Medical Organization Source: ClinicalTrials.gov ↗

First seen Jul 31, 2026 · Last updated Jul 31, 2026

Summary

This pilot study tests whether adding dipyridamole, an approved drug that improves blood flow, to standard care is feasible and safe for pregnant women with early-onset preeclampsia. The trial will enroll 15 hospitalized women between 26 and 34 weeks of pregnancy with high levels of certain placental markers. Researchers will measure how the drug is processed in the body, its side effects, and its effects on placental health, aiming to gather data for a larger future trial.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Dipyridamole (oral tablets)
What this could lead to: If successful, this could pave the way for a larger trial testing whether dipyridamole can slow the placental damage in early-onset preeclampsia, potentially delaying delivery and improving outcomes for mothers and babies.
What could go wrong: This is a small pilot study focused on feasibility and safety, not effectiveness. The drug may not show clear benefits, and there are risks of side effects or complications in a high-risk pregnancy.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HYPERTENSION ,PREGNANCY are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

hypertension, pregnancy-induced preeclampsia

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HYPERTENSION ,PREGNANCY PREECLAMPSIA (PE)

Contacts and locations

Locations

Hadassah University Medical Center

Jerusalem, Israel, 9112001, Israel

More trials for these conditions

Other studies related to the condition(s) this trial covers.